H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) on October 21, keeping the associated price target the same at $90.

Is Halozyme Therapeutics, Inc. (HALO) the Unstoppable Growth Stock to Invest in Now?

The analyst supported the optimistic rating with the company’s growth potential and the stability of its financial prospects, citing the recent success of the MajesTEC-3 trial that showed considerable improvements in progression-free survival (PFS) and overall survival (OS) compared to existing treatments.

The MajesTEC-3 trial pairs Johnson & Johnson’s DARZALEX Faspro with TECVAYLI. According to the analyst, the trial’s outcome boosts Halozyme Therapeutics, Inc.’s (NASDAQ:HALO) royalty base and bolsters evidence for DARZALEX-based regimens, as DARZALEX Faspro is powered by the company’s ENHANZE technology.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that develops, manufactures, and commercializes drug-device combination products through advanced auto-injector technology. They offer commercial or functional benefits, including increased patient comfort and adherence, and enhanced tolerability and convenience.

While we acknowledge the potential of HALO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HALO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.